Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 7Completed 7Terminated 4Unknown 2Not yet recruiting 2Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Breast Neoplasms 5Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 2Colonic Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Stress, Psychological 1Stomach Neoplasms 1Stage III and IV Ovarian Cancer 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Pathologic Complete Response 1Pancreatic Neoplasms 1Osteosarcoma 1Neoplasm, Residual 1Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer 1NSCLC 1Muscle-Invasive Bladder Carcinoma 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Locally Advanced Cervical Cancer 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Fallopian Tube Neoplasms 1Esophageal Neoplasms 1Carcinoma, Ovarian Epithelial 1Bites and Stings 1

Interventions

toripalimab 6Cisplatin 5130-nm albumin-bound paclitaxel 5Drug Therapy 4tislelizumab 3sintilimab 3camrelizumab 3Injections 3Immune Checkpoint Inhibitors 3Fluorouracil 3Carboplatin 3nedaplatin 2anlotinib 2Radiotherapy 2Paclitaxel 2Neoadjuvant Therapy 2Irinotecan 2Esophagectomy 2potassium oxonate 1pembrolizumab 1lenvatinib 1ivarmacitinib 1irinotecan sucrosofate 1Watchful Waiting 1Taxes 1TP protocol 1S 1 (combination) 1Radiotherapy, Intensity-Modulated 1Radiation 1Observation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Esophageal Squamous Cell Carcinoma × Neoadjuvant Therapy × Clear all
NCT07244978 2026-04-24

Neoadjuvant Ivonescimab(AK112) Combined With Chemotherapy in Patients With Resectable Esophageal Squamous Cell Carcinoma

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Not yet recruiting
49 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT06889402 2025-03-21

Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Not yet recruiting
600 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Pathologic Complete Response, Esophageal Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡